Rociletinib hydrobromide (Standard)

Rociletinib hydrobromide (Standard) is the analytical standard of Rociletinib hydrobromide. This product is intended for research and analytical applications. Rociletinib hydrobromide (CO-1686 hydrobromide) is an orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M, and the Ki values for EGFRL858R/T790M and EGFRWT are 21.5 nM and 303.3 nM, respectively.

Product Specifications

CAS Number

[1446700-26-0]

UNSPSC

12352100

Target

EGFR; Reference Standards

Related Pathways

JAK/STAT Signaling; Others; Protein Tyrosine Kinase/RTK

Field of Research

Cancer

Smiles

C=CC(NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(C)=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1)=O.[H]Br

Molecular Formula

C27H29BrF3N7O3

Molecular Weight

636.46

References & Citations

[1]Walter AO, et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 2013 Sep 25.